2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1336321207 MD
Verify on CMS →

PAUL LYDE, MD

Endocrinology, Diabetes & Metabolism Physician in IRVING, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
5K
Medicare Part D claims · 496 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
76%
generic claims · 24% brand-name · higher generic rates reduce patient out-of-pocket costs

What the federal data shows

PAUL LYDE, MD filed 5,471 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in IRVING, Texas, prescribing 76% generic.

5K
Part D claims, 2023
76%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

PAUL LYDE, MD's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

5,471 Top 6% higher than 94% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). Below this entry. 400–600: 90,619 prescribers (7%). Below this entry. 600–800: 56,224 prescribers (4%). Below this entry. 800–1,000: 40,919 prescribers (3%). Below this entry. 1,000–1,200: 31,827 prescribers (2%). Below this entry. 1,200–1,400: 26,224 prescribers (2%). Below this entry. 1,400–1,600: 21,710 prescribers (2%). Below this entry. 1,600–1,800: 19,072 prescribers (1%). Below this entry. 1,800–2,000: 16,451 prescribers (1%). Below this entry. 2,000–2,200: 213,991 prescribers (16%). This entry sits in this band. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic — not verified)

PAUL LYDE, MD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about PAUL LYDE, MD?

Quality data not reported

NPI registry status

Active

Issued 12/03/2007

NPI 1336321207

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

5,471 107% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

Specialty distribution in Texas

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Texas providers

Texas providers

Endocrinology, Diabetes & Metabolism Physician share within Texas

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within Texas

Specialty board-certification context

Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate

Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

PAUL LYDE, MD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD credentials at 6750 N MACARTHUR BLVD, IRVING, TX, 75039, with a listed phone of (972) 556-1616. NPI 1336321207 was issued on 12/03/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what LYDE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 5,471 prescription claims written by this provider, covering 496 Medicare beneficiaries and totaling roughly $1.7 million in drug spend, split 24% brand-name and 76% generic by claim count, with an opioid prescribing rate of 1.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

6750 N MACARTHUR BLVD
IRVING, TX 75039

Provider Details

NPI 1336321207
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials MD
Gender Male
NPI Issued 12/03/2007

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to PAUL LYDE, MD. To verify PAUL LYDE, MD's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

PAUL LYDE, MD — brand share 24.0%
Specialty average (est.)

24% brand-name claims vs 76% generic, on 5,471 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

5,471
Total Claims
$1.7M
Total Drug Cost
496
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
13,778
Total Day Supply
406,528
Brand vs Generic
24% brand / 76% generic
Brand Drug Cost
$1.5M
Generic Drug Cost
$99K
Opioid Claims
62 (1.1% rate)
Antibiotic Claims
107

Patient Demographics

Average Patient Age
73.8 years
Avg HCC Risk Score
1.60
Gender Split
44% female / 56% male
Age Distribution
<65: 37, 65-74: 236, 75-84: 178, 85+: 45

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What PAUL LYDE, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Atorvastatin Calcium
344
Levothyroxine Sodium
218
Metformin Hcl Er
Metformin Hcl
216
Rosuvastatin Calcium
178
Amlodipine Besylate
174
Glimepiride
168
Losartan Potassium
157
Ozempic
Semaglutide
150
Lisinopril
126
Metformin Hcl
125

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How PAUL LYDE, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

PAUL LYDE, MD's 5,471 claims are above the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as LYDE.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is PAUL LYDE, MD's specialty?
PAUL LYDE, MD specializes in Endocrinology, Diabetes & Metabolism Physician and practices in IRVING, Texas. Credentials: MD.
How much does PAUL LYDE, MD prescribe under Medicare Part D?
In 2023, PAUL LYDE, MD wrote 5,471 Medicare Part D claims totaling $1.7M in drug costs for 496 beneficiaries.
Where is PAUL LYDE, MD located?
PAUL LYDE, MD is located at 6750 N MACARTHUR BLVD, IRVING, TX, 75039. Phone: (972) 556-1616.
What is PAUL LYDE, MD's NPI number?
PAUL LYDE, MD's National Provider Identifier (NPI) is 1336321207, issued on 12/03/2007.
Does PAUL LYDE, MD prescribe more brand-name or generic drugs?
PAUL LYDE, MD's prescribing is 24% brand-name and 76% generic drugs by claim count, with $1.5M in brand drug costs.
Does PAUL LYDE, MD prescribe opioids?
Yes, PAUL LYDE, MD had 62 opioid claims in 2023 with an opioid prescribing rate of 1.1%.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does PAUL LYDE, MD prescribe most often?
Based on 2023 Medicare Part D data, PAUL LYDE, MD's most frequently prescribed drugs include Atorvastatin Calcium, Levothyroxine Sodium, Metformin Hcl Er. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does PAUL LYDE, MD accept Medicare?
PAUL LYDE, MD appears in CMS Medicare data with 5,471 Part D claims and 496 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify PAUL LYDE, MD's credentials?
PAUL LYDE, MD's NPI is 1336321207 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology